Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation

Annals of Hematology

Volumn 86, Issue 8, 2007, Pages 583-589

  Blau, I W ^a   Schmidt Hieber, Martin ^a   Leschinger, N ^a   Goldner H ^a   Knauf, W ^b   Hopfenmuller W ^a   Thiel, E ^a   Blau, O ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Bethanien Krankenhaus Frankfurt   (Germany)

Author keywords

Chimerism; Engraftment; Fludarabine; Reduced intensity; SCT; Treosulfan

Indexed keywords

CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; BUSULFAN; CHIMERISM; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 34347387789     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0294-6     Document Type: Article

References (37)

1. Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel PG, Niethammer D, Beck J (1997) Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: The impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 19:697-702
2. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T (2005) How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 35:107-119
3. Balon J, Halaburda K, Bieniaszewska M, Reichert M, Bieniaszewski L, Piekarska A, Pawlowski R, Hellmann A (2005) Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant 35:1083-1088
4. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S (2004) Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced-intensity conditioning regimens. Crit Rev Oncol Hematol 51:171-189
5. Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233-241
6. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123
7. Butcher BW, Collins RH (2005) The graft-versus-lymphoma effect: Clinical review and future opportunities. Bone Marrow Transplant 36:1-17
8. Byrd JC, Stilgenbauer S, Flinn IW (2004) Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 1:163-183
9. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dolken G, Freund M (2004) Treosulfan and fludarabine: A new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 15:725-731
10. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale, G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078
11. De Greef GE, van Putten WL, Boogaerts M, Huijgens PC, Verdonck LF, Vellenga E, Theobald M, Jacky E, Lowenberg B; The Dutch-Belgian Hemato-Oncology Co-operative Group HOVON; The Swiss Group for Clinical Cancer Research SAKK (2005) Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol 128:184-191
12. Du BA, Meier W, Luck HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C, Richter B, Wagner U (2002) Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: A randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13:251-257
13. Faderl S, Estrov Z (2004) Hematopoietic recovery following induction therapy of acute leukemias: Prognostic implications and a new look at the definition of remission. Leuk Lymphoma 45:67-71
14. Fichtner I, Becker M, Baumgart J (2003) Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL). Eur J Cancer 39:801-807
15. Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs-host disease: pathobiology and management. Exp Hematol 29:259-277
16. Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S, Ramberg R, Thomas ED (1986) Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 67:811-816
17. Huss R, Deeg HJ, Gooley T, Bryant E, Leisenring W, Clift R, Buckner CD, Martin P, Storb R, Appelbaum FR (1996) Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 18:767-776
18. Jimenez-Velasco A, Barrios M, Roman-Gomez J, Navarro G, Buno I, Castillejo JA, Rodriguez AI, Garcia-Gemar G, Torres A, Heiniger AI (2005) Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 19:336-343
19. Keating MJ (1990) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17:49-62
20. Lamba R, Abella E, Kukuruga D, Klein J, Savasan S, Abidi MH, Mohamed A, Peres E, (2004) Mixed hematopoietic chimerism on day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 18:1681-1686
21. Lee SJ, Vogelsang G, Flowers ME (2003) Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9:215-233
22. MacKinnon S (2000) Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 110:12-17
23. McSweeney PA, Storb R (1999) Mixed chimerism: Preclinical studies and clinical applications. Biol Blood Marrow Transplant 5:192-203
24. Meinhardt G, Dayyani F, Jahrsdorfer B, Baumgart J, Emmerich B, Schmidmaier R (2003) Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol 122:892-899
25. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, Milpied N, Moreau P, Bordigoni P, Kuentz M, Sadoun A, Cahn JY, Socie G, Thomas X, Arnaud P, Raus N, Lheritier V, Pigneux A, Boiron JM (2001) Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 19:3340-3349
26. Ploemacher RE (2000) Preclinical report on treosulfan as a conditioning agent in syngeneic and allogeneic bone marrow transplantation. Medac internal report, March 17
27. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828
28. Schetelig J, Bornhauser M, Kiehl M, Schwerdtfeger R, Kroger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W (2004) Cooperative German Transplant Study Group. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation - a retrospective analysis. Bone Marrow Transplant 33:483-490
29. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, Bornhauser M, Ehninger G, Berdel WE, Baumgart J, Harstrick A, Bojko P, Wolf HH, Schindler AE, Seeber S (2000) Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 6:4209-4216
30. Schmittel A, Scheulen ME, Bechrakis NE, Strumberg D, Baumgart J, Bornfeld N, Foerster MH, Thiel E, Keilholz U (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15:205-207
31. Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A (2005) Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: Older age is no longer a contraindication when using reduced-intensity conditioning. Leukemia 19:7-12
32. Sjoo F, Hassan Z, Abedi-Valugerdi M, Griskevicius L, Nilsson C, Remberger M, Aschan J, Concha H, Gaughan U, Hassan M (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34:115-121
33. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763
34. Valcarcel D, Martino R, Caballero D, Mateos MV, Perez-Simon JA, Canals C, Fernandez F, Bargay J, Muniz-Diaz E, Gonzalez M, San Miguel JF, Sierra J (2003) Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 31:387-392
35. Van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan PM, Vossen JM (1994) Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 83:3059-3067
36. Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT, Hadfield JA, Dawson MJ, Down JD (2000) Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 60:5470-5478
37. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socie G, Golmard JL, Jouet JP (2006) French Society of bone marrow transplantation and cell therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of bone marrow transplantation and cell therapy. J Clin Oncol 24:5695-5702